Veterinary Molecular Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Kit and Reagents, Software and Services), By Application (Infectious Diseases, Genetics, Other), By Technology (PCR, Microarray, DNA Sequencing), By Region and Competition, 2020-2030F

Market Overview

The Global Veterinary Molecular Diagnostic Market, valued at USD 1.19 Billion in 2024, is projected to experience a CAGR of 8.90% to reach USD 1.98 Billion by 2030. The Global Veterinary Molecular Diagnostic Market involves the utilization of specialized laboratory techniques to analyze an animal's DNA, RNA, or other proteins for the accurate detection, identification, and genotyping of diseases or genetic predispositions. Market growth is primarily driven by the increasing prevalence of infectious animal diseases globally, rising companion animal ownership, and the sustained demand for safe, animal-derived food products. For instance, according to the World Organisation for Animal Health (WOAH), the reported number of avian influenza outbreaks in mammals more than doubled in 2024, reaching 1,022 outbreaks across 55 countries, compared to 459 outbreaks in 2023, underscoring the critical need for advanced diagnostics.

However, a significant challenge impeding market expansion is the substantial cost associated with developing, producing, and maintaining advanced molecular diagnostic technologies and their associated testing, which can limit accessibility for some veterinary practices.

Key Market Drivers

The global veterinary molecular diagnostic market is significantly influenced by the increased prevalence of animal diseases, which necessitates advanced and rapid detection methods to mitigate health and economic impacts. The continuous emergence and spread of infectious diseases across diverse animal populations, including both livestock and companion animals, underscore a critical need for precise diagnostic capabilities. For example, according to the World Organisation for Animal Health, in October 2024, African Swine Fever outbreaks resulted in 195,191 reported cases and 222,174 animal losses among domestic pigs across 16 countries and territories, highlighting the severity and widespread nature of animal health challenges. This heightened disease burden drives consistent demand for sophisticated molecular diagnostic tools that can quickly and accurately identify pathogens, enabling timely intervention and disease control strategies.

Further propelling market expansion are significant advancements in molecular diagnostic technologies. Innovations in techniques such as Polymerase Chain Reaction, next-generation sequencing, and microarrays offer improved sensitivity, specificity, and efficiency for detecting various animal diseases and genetic predispositions. These technological leaps are crucial for developing diagnostic solutions that provide quicker, more reliable results, moving veterinary care toward more proactive and personalized approaches. Illustratively, according to a Basepaws press release, in October 2023, Zoetis launched the Basepaws Breed + Health Dog DNA Test, which includes over 280 genetic markers linked to various canine hereditary conditions, showcasing the development of accessible, comprehensive genetic screening tools for pets. Moreover, the broader market benefits from sustained investment in animal health infrastructure; according to the US Department of Agriculture’s Animal and Plant Health Inspection Service, in May 2024, over $22.2 million was awarded to 81 projects across 48 states, universities, and veterinary diagnostic laboratories to enhance early detection and response to animal diseases, further bolstering diagnostic capabilities.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with developing, producing, and maintaining advanced molecular diagnostic technologies and their associated testing presents a significant impediment to the growth of the Global Veterinary Molecular Diagnostic Market. This financial burden directly limits the accessibility of these crucial tools for many veterinary practices, particularly smaller clinics or those operating in regions with constrained budgets. The significant upfront investment required for purchasing specialized equipment, coupled with ongoing expenses for reagents, consumables, and the continuous professional development needed for staff, creates a formidable barrier to adoption.

This cost impediment significantly hampers market expansion by restricting widespread adoption. When veterinary practices are unable to invest in these advanced technologies due to cost, it limits their ability to offer comprehensive and early disease detection services, despite the rising demand for such accuracy. For instance, according to the American Pet Products Association, in 2023, approximately USD 38.3 billion was spent on veterinary care, product sales, and other related services in the United States. Despite this substantial overall expenditure on animal health, the specific high cost of molecular diagnostic equipment and associated tests can still create a significant financial hurdle for individual practices, thereby limiting the market's expansion into a broader base of veterinary service providers.

Key Market Trends

The shift towards point-of-care molecular diagnostics represents a significant evolution in veterinary medicine, enabling veterinarians to perform advanced tests directly at the animal's location or within the clinic. This trend reduces turnaround times for results, facilitating immediate treatment decisions and improving patient outcomes. Such accessibility is particularly crucial for time-sensitive conditions and in remote settings where centralized laboratories are not readily available. According to the American Pet Products Association (APPA), in 2023, U. S. spending on veterinary care reached $31.4 billion, demonstrating the substantial financial commitment to animal health that supports the adoption of efficient diagnostic tools. For example, in December 2024, Zomedica Corp. launched the canine NT-proBNP POC test assay for cardiac complications and the Truforma In-clinic Biosensor Testing Platform, showcasing the ongoing development of rapid, on-site molecular diagnostic solutions.

Another pivotal trend is the increasing integration of artificial intelligence in diagnostic workflows. AI systems enhance the speed and accuracy of analyzing complex diagnostic data, such as imaging and laboratory results, assisting veterinarians in making more informed decisions. This integration streamlines operations, mitigates human error, and allows veterinary professionals to focus more on patient care. According to the American Veterinary Medical Association (AVMA), the estimated total number of U. S. veterinarians was 130,415 as of December 31, 2024, highlighting a large professional base that can benefit from AI-driven efficiencies. Illustratively, in June 2025, Zoetis launched AI Masses, an AI-powered analysis technology designed for integration into its Vetscan Imagyst analyzer, further demonstrating the application of AI to improve diagnostic capabilities within the market.

Segmental Insights

The Kits and Reagents segment is a key driver within the Global Veterinary Molecular Diagnostic Market, experiencing rapid growth due to its recurring consumption model. These consumables are essential for every molecular test, ensuring continuous demand as the volume of veterinary diagnostic testing increases, particularly with the rising prevalence of animal diseases and outbreaks globally. Advances in molecular diagnostic technologies, such as PCR, further boost this segment by enabling faster, more accurate, and user-friendly testing workflows, which often rely on specific kits and reagents for effective pathogen detection and disease management. The widespread adoption of these advanced diagnostic tools in veterinary hospitals and clinics solidifies the segment's growth trajectory. The Kits and Reagents segment is a key driver within the Global Veterinary Molecular Diagnostic Market, experiencing rapid growth due to its recurring consumption model. These consumables are essential for every molecular test, ensuring continuous demand as the volume of veterinary diagnostic testing increases, particularly with the rising prevalence of animal diseases and outbreaks globally. Advances in molecular diagnostic technologies, such as PCR, further boost this segment by enabling faster, more accurate, and user-friendly testing workflows, which often rely on specific kits and reagents for effective pathogen detection and disease management. The widespread adoption of these advanced diagnostic tools in veterinary hospitals and clinics solidifies the segment's growth trajectory.

Regional Insights

North America is the dominant region in the global veterinary molecular diagnostic market due to several key factors. The region benefits from a well-established veterinary healthcare infrastructure, a high rate of pet ownership, and significant expenditure on animal health, reflecting a strong emphasis on preventive care and advanced diagnostics for companion animals. Furthermore, robust research and development activities and the presence of major industry players drive technological advancements in molecular diagnostics. Supportive regulatory frameworks, involving bodies such as the United States Department of Agriculture (USDA) and the Food and Drug Administration (FDA) Center for Veterinary Medicine, also facilitate the adoption and innovation of veterinary diagnostic products. This combination of advanced facilities, substantial investment, and a proactive regulatory environment solidifies North America's leading position.

Recent Developments

• In July 2025, Alveo Technologies and Royal GD announced an expanded partnership to develop rapid molecular tests for significant poultry diseases. This collaboration aimed to introduce additional diagnostic panels, including a notifiable disease panel and an avian respiratory panel. These new tests would build upon their existing successful launch of the Alveo Sense™ Avian Influenza test. The expanded initiative focused on addressing the demand for prompt molecular diagnostics at the point of need, facilitating quicker identification of pathogens and thereby enhancing biosecurity and disease control in poultry. The objective was to enable rapid decision-making in veterinary practices.

• In June 2025, Enalees introduced Rhéa®, a new collection of rapid molecular diagnostic tests designed for ruminants. This product launch represented a strategic milestone for the company's research and development, following its previous rollouts for equine and companion animal diagnostics. The Rhéa® range offered a point-of-care solution, enabling veterinarians to detect pathogens directly in the field without requiring laboratory sample transport. The initial Rhéa® Vector-Borne Diseases panel was capable of simultaneously identifying four major pathogens in under 40 minutes, supporting immediate diagnostic and treatment decisions for cattle, sheep, and goats.

• In June 2025, bioMérieux launched VETFIRE™, a ready-to-use PCR kit for equine infectious respiratory diseases. This new molecular diagnostic test provided highly accurate results within 20 minutes from a nasopharyngeal swab. The VETFIRE™ test was designed to simultaneously detect seven infectious respiratory pathogens in horses. A significant feature of this PCR-based test was its ability to distinguish between viral and bacterial infections, which played a crucial role in promoting appropriate antibiotic stewardship and reducing the risk of antimicrobial resistance in equine healthcare. The test became commercially available in the United Kingdom, Ireland, and France.

• In February 2025, Oxford Nanopore and PathoSense announced a strategic collaboration to integrate real-time sequencing into European veterinary infectious disease diagnostics. This partnership aimed to provide veterinarians across Europe with advanced molecular sensing technology. The collaboration sought to streamline testing by consolidating various traditional infectious disease tests into a single, accessible, sequencing-based solution. Powered by Oxford Nanopore's sequencing technology, PathoSense and its partner laboratories planned to offer comprehensive pathogen detection, delivering deeper insights for informed treatment decisions for both livestock and pets, thereby advancing animal healthcare.

Key Market Players

• Biochek BV
• Biomerieux SA
• Bioneer Corporation
• Idexx Laboratories Inc.
• Ingenetix GmbH
• Neogen Corporation
• Thermo Fischer Scientific Inc.
• Veterinary Molecular Diagnostics Inc.
• Biomedica Medizinprodukte GmbH
• Novacyt Group

Report Scope:

In this report, the Global Veterinary Molecular Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Molecular Diagnostic Market, By Product:

o   Instruments

o   Kit and Reagents

o   Software and Services

• Veterinary Molecular Diagnostic Market, By Application:

o   Infectious Diseases

o   Genetics

o   Other

• Veterinary Molecular Diagnostic Market, By Technology:

o   PCR

o   Microarray

o   DNA Sequencing

• Veterinary Molecular Diagnostic Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Veterinary Molecular Diagnostic Market.

Available Customizations:

Global Veterinary Molecular Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Veterinary Molecular Diagnostic Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]